[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,903,747
  • Shares Outstanding, K 148,805
  • Annual Sales, $ 0 K
  • Annual Income, $ -766,630 K
  • EBIT $ -1,165 M
  • EBITDA $ -1,155 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.20

Options Overview Details

View History
  • Implied Volatility 46.53% (-0.42%)
  • Historical Volatility 41.66%
  • IV Percentile 4%
  • IV Rank 34.43%
  • IV High 90.62% on 11/04/25
  • IV Low 23.38% on 08/26/26
  • Expected Move (DTE 20) 2.21 (3.69%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 120
  • Volume Avg (30-Day) 543
  • Put/Call OI Ratio 2.35
  • Today's Open Interest 97,094
  • Open Int (30-Day) 93,273
  • Expected Range 57.62 to 62.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.84
  • Number of Estimates 2
  • High Estimate $-1.67
  • Low Estimate $-2.00
  • Prior Year $-1.56
  • Growth Rate Est. (year over year) -17.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.47 +14.04%
on 07/29/26
63.98 -6.48%
on 08/21/26
+5.24 (+9.59%)
since 07/28/26
3-Month
45.30 +32.09%
on 06/11/26
63.98 -6.48%
on 08/21/26
+8.77 (+17.19%)
since 05/28/26
52-Week
30.32 +97.34%
on 08/29/25
65.00 -7.95%
on 02/25/26
+29.06 (+94.46%)
since 08/28/25

Most Recent Stories

More News
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats...

PCVX : 59.83 (-2.16%)
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats...

PCVX : 59.83 (-2.16%)
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027

PCVX : 59.83 (-2.16%)
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline...

PCVX : 59.83 (-2.16%)
Vaxcyte's Pipeline Timing Assumptions Haven't Been This Visible in Years

Barchart Research What to Expect from PCVX Earnings PCVX Generated August 4, 2026 Current Price $54.69 EPS Estimate $$-1.47 Consensus Rating Moderate Buy Average Move 5.17% Vaxcyte's Pipeline Timing Assumptions...

PCVX : 59.83 (-2.16%)
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one...

PCVX : 59.83 (-2.16%)
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that...

PCVX : 59.83 (-2.16%)
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation...

PCVX : 59.83 (-2.16%)
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A...

PCVX : 59.83 (-2.16%)
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia...

PCVX : 59.83 (-2.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 64.53
2nd Resistance Point 63.45
1st Resistance Point 61.65
Last Price 59.83
1st Support Level 58.76
2nd Support Level 57.67
3rd Support Level 55.87

See More

52-Week High 65.00
Last Price 59.83
Fibonacci 61.8% 51.75
Fibonacci 50% 47.66
Fibonacci 38.2% 43.57
52-Week Low 30.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.